Improving quality control for CAR T cell therapies
Drug Discovery World
AUGUST 10, 2022
Finally, in 2017, after years of improving T cell engineering techniques, the first chimeric antigen receptor (CAR) T cell therapy received FDA approval. CAR T cells are T cells that have been trained to attack tumours. If the gene does not integrate into the genome, the cell will not become a CAR T cell.
246 
Let's personalize your content